Racemic Ketamine vs Esketamine: Pharmacological Comparison

Understanding the Two Forms of Ketamine

Racemic ketamine and esketamine are closely related but pharmacologically distinct compounds, and the differences between them carry significant implications for clinical practice, research, regulation, and patient access. As ketamine-based treatments have become more widespread, the question of which form is preferable has become one of the most debated topics in the field.

Ketamine is a chiral molecule, meaning it exists in two mirror-image forms called enantiomers. The equal mixture of both enantiomers — S-ketamine and R-ketamine — is known as racemic ketamine. Esketamine is the isolated S-enantiomer, while arketamine refers to the R-enantiomer. Racemic ketamine has been used clinically since 1970, while esketamine (brand name Spravato) received FDA approval in 2019 specifically for treatment-resistant depression.

Pharmacological Differences

NMDA Receptor Binding

The most significant pharmacological distinction between the two forms relates to their affinity for the NMDA receptor — the primary molecular target responsible for ketamine's anesthetic and antidepressant effects. For a detailed explanation, see our NMDA receptor glossary entry.

Esketamine binds to the NMDA receptor with approximately three to four times greater affinity than arketamine. As a result, esketamine is a more potent NMDA receptor antagonist on a milligram-per-milligram basis, and it produces anesthetic and dissociative effects at lower doses than racemic ketamine. This higher potency is the basis for the dose differential seen in clinical practice — a therapeutic dose of esketamine is typically lower than the equivalent dose of racemic ketamine.

Racemic ketamine, being a 50:50 mixture of both enantiomers, has an intermediate NMDA binding profile. Its overall pharmacological effect reflects the combined contributions of both S- and R-enantiomers, which may differ in important ways beyond simple NMDA receptor antagonism.

Beyond NMDA: Additional Receptor Interactions

Both enantiomers interact with multiple receptor systems beyond NMDA, but their relative affinities differ:

• Opioid receptors — Both enantiomers have activity at opioid receptors, with esketamine showing greater affinity for mu and kappa opioid receptors
• Dopamine transporters — Esketamine has greater affinity for the dopamine transporter, which may contribute to its more prominent psychoactive and potentially mood-elevating effects
• Sigma receptors — Both enantiomers interact with sigma receptors, though their functional significance remains under investigation
• AMPA receptors — The downstream effects on AMPA receptor-mediated signaling may differ between enantiomers, with arketamine potentially producing more sustained AMPA activation through distinct mechanisms
• HCN channels — Arketamine has greater activity at hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which may contribute to unique neuroplastic effects

Metabolic Pathways

Racemic ketamine and esketamine are metabolized primarily by cytochrome P450 enzymes in the liver (CYP3A4 and CYP2B6). Both are converted to their respective norketamine metabolites — see our pharmacology guide for more detail — S-norketamine and R-norketamine — which have their own pharmacological activity. The metabolites may contribute meaningfully to the therapeutic effects, particularly with oral or sublingual administration where first-pass metabolism is significant.

Esketamine is metabolized more rapidly than arketamine, resulting in a somewhat shorter duration of action. In clinical practice, this translates to a slightly shorter dissociative experience with esketamine compared to an equivalent dose of racemic ketamine.

Clinical Efficacy Comparison

Evidence for Racemic Ketamine

Racemic ketamine has the larger overall evidence base, with hundreds of studies spanning more than two decades. The foundational clinical trials — including the landmark Yale (2000) and NIMH (2006) studies described in our history of ketamine — all used racemic ketamine. Meta-analyses consistently demonstrate:

• Rapid antidepressant effects within hours of a single IV infusion
• Response rates of 60-70% in treatment-resistant depression
• Significant reductions in suicidal ideation
• Efficacy across depression subtypes, PTSD, anxiety, and chronic pain

However, racemic ketamine for psychiatric indications is used off-label, as it has never undergone the formal FDA approval process for these conditions.

Evidence for Esketamine

Esketamine has a more targeted evidence base, derived primarily from the registration trials conducted by Janssen Pharmaceuticals for the Spravato approval:

• TRANSFORM trials (TRD): Demonstrated statistically significant improvements in depression scores compared to placebo, though effect sizes were modest in some studies
• ASPIRE trials (suicidal ideation): Showed rapid improvement in depressive symptoms in patients with acute suicidal ideation
• SUSTAIN trials (long-term): Demonstrated that continued esketamine treatment reduced the risk of relapse

Head-to-Head Comparisons

Direct comparisons between racemic ketamine and esketamine are limited but growing. A 2021 meta-analysis published in JAMA Psychiatry found that IV racemic ketamine produced somewhat larger acute antidepressant effect sizes than intranasal esketamine, though the authors noted that differences in route of administration, dosing, and study populations complicated direct comparison.

A 2023 randomized trial comparing IV racemic ketamine to intranasal esketamine found superior antidepressant efficacy for IV racemic ketamine at 24 hours, with the difference attenuating over subsequent days. These findings have generated debate about whether the apparent superiority reflects a true pharmacological difference between the compounds or simply the higher bioavailability of IV versus intranasal administration.

Regulatory and Access Differences

FDA Approval Status

This is the most consequential practical difference between the two forms:

• Esketamine (Spravato) is FDA-approved for TRD and MDD with suicidal ideation. As an approved product, it has a standardized formulation, dosing protocol, and safety monitoring framework (the REMS program).
• Racemic ketamine is FDA-approved only as an anesthetic. Its psychiatric use is entirely off-label, with no standardized treatment protocol, no REMS requirements, and no FDA-mandated safety monitoring.

Insurance Coverage

The FDA approval status directly affects insurance coverage:

• Spravato is covered by most commercial insurance plans and Medicare Part D, typically with prior authorization. Out-of-pocket costs with insurance range from minimal copays to several hundred dollars per session.
• Racemic ketamine for psychiatric use is generally not covered by insurance, as insurers typically do not cover off-label IV infusions. Patients usually pay out of pocket, with costs ranging from $400 to $800 per infusion.

Administration Setting

• Spravato must be administered in a certified healthcare setting under the REMS program, with two-hour post-dose monitoring
• Racemic IV ketamine is administered in clinics and medical offices, with monitoring protocols determined by the individual provider
• Compounded racemic ketamine (sublingual, intranasal) can be prescribed for at-home use, with varying levels of clinical oversight

Cost Comparison

Cost is a major factor in clinical decision-making:

• Spravato without insurance: Approximately $600-$900 per session at list price
• Spravato with insurance: Variable, often $0-$200 per session after deductible
• IV racemic ketamine: $400-$800 per infusion, typically out of pocket
• Compounded sublingual ketamine: $50-$150 per month for medications, plus consultation fees

For patients with insurance coverage for Spravato, the out-of-pocket cost may be lower than self-pay IV racemic ketamine despite the higher list price. For patients without Spravato coverage, racemic ketamine — particularly compounded formulations — may be significantly more affordable.

The Arketamine Question

A growing body of research suggests that arketamine (R-ketamine), the enantiomer not present in Spravato, may have unique and potentially superior antidepressant properties:

• Preclinical studies have shown that arketamine produces longer-lasting antidepressant effects than esketamine in animal models
• Arketamine appears to produce less dissociation and fewer psychotomimetic effects
• Its antidepressant mechanism may rely more heavily on AMPA receptor activation and BDNF release than on NMDA blockade
• A Phase 2 clinical trial (PCN-101/arketamine) has shown promising results in treatment-resistant depression

If arketamine ultimately proves effective, it would raise the question of whether racemic ketamine — which contains both enantiomers — may offer therapeutic advantages over esketamine alone by providing the combined benefits of both the S- and R-forms.

Clinical Decision-Making

When Esketamine May Be Preferred

• Insurance coverage is available, making cost manageable
• The patient values a standardized, FDA-approved treatment protocol
• The prescriber prefers the structure and safety requirements of the REMS program
• The patient has not responded to other treatments and meets the specific TRD or suicidal ideation indication

When Racemic Ketamine May Be Preferred

• The patient does not have insurance coverage for Spravato
• The clinician desires greater flexibility in dosing and administration
• IV administration is preferred for its higher bioavailability and dose titration capability
• The patient is being treated for conditions other than TRD (e.g., PTSD, chronic pain, anxiety), where racemic ketamine has a broader evidence base
• Integration with psychotherapy is a treatment priority

Individual Response Variability

Some patients respond to one form but not the other. This clinical observation has not been fully explained by the existing pharmacological data but may relate to the differential receptor profiles of the two enantiomers, individual variations in metabolism, or other factors. Clinicians who have experience with both forms often recommend trying the alternative if the initial form is ineffective.

Note: This article is for educational purposes only and does not constitute medical advice. For help choosing a provider, see how to find a ketamine clinic. The choice between racemic ketamine and esketamine should be made in consultation with a qualified healthcare provider based on individual clinical circumstances. For more on the underlying pharmacology, see our ketamine pharmacology guide.

References

• MedlinePlus: Esketamine Nasal Spray — National Library of Medicine drug information on Spravato (esketamine) pharmacology and indications
• MedlinePlus: Ketamine Injection — Drug information on racemic ketamine's clinical uses and pharmacological profile
• Ketamine Pharmacology: An Update — NIH review comparing enantiomer pharmacodynamics and receptor binding profiles
• StatPearls: Ketamine — Comprehensive clinical reference on ketamine enantiomers, metabolism, and clinical considerations